Home

Astrazeneca Pharma India Ltd PE Ratio

Image

Astrazeneca Pharma India Ltd

NSE: ASTRAZEN

PE

136.5

Last updated on: Jan 14, 2025

Key Highlights

  • The P/E Ratio of Astrazeneca Pharma India Ltd is 136.5 as of 14 Jan 15:30 PM .
  • The P/E Ratio of Astrazeneca Pharma India Ltd changed from 82.8 on March 2020 to 82.4 on March 2024 . This represents a CAGR of -0.10% over 5 years.
  • The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 7030 as of 14 Jan 15:30 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 21.0 to 40.0 in 5 years. This represents a CAGR of 13.75%.
  • The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.4. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.6. The PE Ratio of Textiles industry is 36.9 in 2024.

Historical P/E Ratio of Astrazeneca Pharma India Ltd

No data available

Company Fundamentals for Astrazeneca Pharma India Ltd

Image

Astrazeneca Pharma India Ltd

NSE: ASTRAZEN

Share Price

₹ 7030.35

-13.35 (-0.19%)

stock direction

Last updated on: Jan 14, 2025

Market Price of Astrazeneca Pharma India Ltd

1M

1Y

3Y

5Y

Monitoring Astrazeneca Pharma India Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
14 Jan 20257030.35
13 Jan 20257043.7
10 Jan 20256912.5
09 Jan 20257076
08 Jan 20256892.55
07 Jan 20257092.85
06 Jan 20257251.75
03 Jan 20257113.75
02 Jan 20257137.75
01 Jan 20257206.4

BlinkX Score for Astrazeneca Pharma India Ltd

Asset Value vs Market Value of Astrazeneca Pharma India Ltd

Market Value

0

Asset Value

0

* All values are in ₹ crores

Competitive Comparison of P/E Ratio

Company
leftMarket Capright
Astrazeneca Pharma India Ltd17575
Sun Pharmaceuticals Industries Ltd424382
Divis Laboratories Ltd159224
Cipla Ltd116943
Dr Reddys Laboratories Ltd111588

PE Ratio of Astrazeneca Pharma India Ltd Explained

``

17575

Market cap

81

Earnings

136.5X

PE Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Astrazeneca Pharma India Ltd

No data available

* All values are in crore

Historical Revenue, EBITDA and Net Profit of Astrazeneca Pharma India Ltd

Revenue

EBITDA

Net Profit

No data available

* All values are in crore

Historical Dividend Payout of Astrazeneca Pharma India Ltd

No data available

* All values are in %

About Astrazeneca Pharma India Ltd

  • AstraZeneca Pharma India (APIL) was incorporated on July 11, 1979.
  • The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
  • The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
  • Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

Astrazeneca Pharma India Ltd News Hub

AstraZeneca slumps on recording dismal Q1 performance

Revenue from operations jumped 31.15% year on year (YoY) to Rs 387.52 crore in the quarter ended 30

Read more

2024-08-08 00:00:00

Astrazeneca Pharma India reports standalone net loss of Rs 11.79 crore in the June 2024 quarter

Net loss of Astrazeneca Pharma India reported to Rs 11.79 crore in the quarter ended June 2024 as ag

Read more

2024-08-08 00:00:00

Astrazenenca Pharma gets CDSCO nod to import Durvalumab solutions

Durvalumab (IMFINZI) in combination with chemotherapy as neoadjuvant treatment, followed by IMFINZI

Read more

2024-09-24 00:00:00

Astrazeneca Pharma India Ltd leads gainers in 'A' group

Sapphire Foods India Ltd, Godawari Power & Ispat Ltd, Firstsource Solutions Ltd and National Alumini

Read more

2024-09-24 00:00:00

Product Composition by Percentage (Revenue)

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Astrazeneca Pharma India Ltd

What is the current PE Ratio of Astrazeneca Pharma India Ltd?

The Current PE Ratio of Astrazeneca Pharma India Ltd is 136.54 as on 14 Jan 2025.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 14 Jan 2025.

What was the PE Ratio of Astrazeneca Pharma India Ltd last year?

The PE Ratio of Astrazeneca Pharma India Ltd was 81.75 last year, now the PE ratio is 136.54, showing a year-on-year growth of 67.0%.

What does the PE Ratio of Astrazeneca Pharma India Ltd indicate about its stock?

The PE Ratio of Astrazeneca Pharma India Ltd is 136.54. This ratio indicates that investors are willing to pay 136.54 times the earnings per share for each share of Astrazeneca Pharma India Ltd.

What is the PE Ratio Growth of Astrazeneca Pharma India Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Astrazeneca Pharma India Ltd grew by 67.0% whereas, the EPS ratio grew by -446.8.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions